From the bench to market
1 / 6

From the Bench to Market - PowerPoint PPT Presentation

  • Uploaded on

From the Bench to Market. Bridging the Gaps for Early Stage Development in a Difficult Economy. Background.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'From the Bench to Market' - kata

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
From the bench to market

From the Bench to Market

Bridging the Gaps for Early Stage Development in a Difficult Economy


  • Joined PDL BioPharma in 2006 with 1100 employees, as it transitioned from being a leading provider of antibody humanization technology to a product-driven enterprise with three commercial drugs on the market and a strong pipeline of therapies in development.

    • Within a year hedge fund investor prompted the sell off of the commercial products

  • In 2008, the PDL BioPharma R&D programs were spun out to form Facet Biotech Corporation with approximately 200 employees

Navigating the downturn at facet responding to shareholder pressure
Navigating the Downturn at Facet:Responding to Shareholder Pressure

  • Narrowed our focus to a single therapeutic area

    • Evaluated additional early stage clinical candidates to strengthen our existing pipeline

  • Evaluated our platform technology to create business opportunities

  • Selective effort to reduce burn rate

  • Create sustainability via partnering our pipeline programs with Big Pharma

Partnering to create sustainability
Partnering to Create Sustainability

  • The biotech industry raised a record $55.8 billion in 2009 despite hesitant stock and venture capital markets, as drug-company partnerships fed the cash-burning startups that develop new therapies.

  • Represents a jump of 85 percent over the $30.1 billion recorded in 2008

  • 2009 results driven by $37 billion in financial partnerships through which large drug companies license technologies or experimental remedies from biotech startups

    • Limit growth of the start up if forced to cede control over most promising developments

      • Farm for Big Pharma


Impact on ip portfolio management
Impact on IP Portfolio Management

  • Increased pressure to enter license agreements with academic institutions to bridge the gap for reduced R&D effort in-house

    • IP ownership issues

    • Coordinating patent prosecution to protect the candidate molecule

      • Objectives of the institution and the company may conflict with respect to claim scope

    • Use of research materials outside the scope of the agreement

Impact on ip portfolio management1
Impact on IP Portfolio Management

  • Collaboration agreements with Big Pharma

    • Working successfully in joint patent committee setting

    • Becoming the target

      • Assessing IP portfolio for strengths and weakness in advance of due diligence